PL3365373T3 - Molekuły wiążące, które hamują wzrost nowotworu - Google Patents
Molekuły wiążące, które hamują wzrost nowotworuInfo
- Publication number
- PL3365373T3 PL3365373T3 PL16794080T PL16794080T PL3365373T3 PL 3365373 T3 PL3365373 T3 PL 3365373T3 PL 16794080 T PL16794080 T PL 16794080T PL 16794080 T PL16794080 T PL 16794080T PL 3365373 T3 PL3365373 T3 PL 3365373T3
- Authority
- PL
- Poland
- Prior art keywords
- binding molecules
- cancer growth
- inhibit cancer
- inhibit
- growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15191343 | 2015-10-23 | ||
EP16168647 | 2016-05-06 | ||
PCT/NL2016/050726 WO2017069628A2 (en) | 2015-10-23 | 2016-10-21 | Binding molecules that inhibit cancer growth |
EP16794080.8A EP3365373B1 (en) | 2015-10-23 | 2016-10-21 | Binding molecules that inhibit cancer growth |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3365373T3 true PL3365373T3 (pl) | 2021-08-23 |
Family
ID=57190021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16794080T PL3365373T3 (pl) | 2015-10-23 | 2016-10-21 | Molekuły wiążące, które hamują wzrost nowotworu |
Country Status (27)
Country | Link |
---|---|
US (2) | US11939394B2 (pl) |
EP (2) | EP3912998A3 (pl) |
JP (3) | JP7296728B2 (pl) |
KR (1) | KR20180100305A (pl) |
CN (2) | CN115925944A (pl) |
AU (2) | AU2016340764B2 (pl) |
BR (1) | BR112018008068A2 (pl) |
CA (1) | CA3002957A1 (pl) |
CY (1) | CY1124108T1 (pl) |
DK (1) | DK3365373T3 (pl) |
EA (1) | EA201890866A1 (pl) |
ES (1) | ES2865482T3 (pl) |
HK (1) | HK1253914A1 (pl) |
HR (1) | HRP20210483T1 (pl) |
HU (1) | HUE055222T2 (pl) |
LT (1) | LT3365373T (pl) |
MA (2) | MA45517B1 (pl) |
MD (1) | MD3365373T2 (pl) |
MX (2) | MX2018004988A (pl) |
NZ (1) | NZ742290A (pl) |
PL (1) | PL3365373T3 (pl) |
RS (1) | RS61800B1 (pl) |
SG (1) | SG11201803359VA (pl) |
SI (1) | SI3365373T1 (pl) |
SM (1) | SMT202100230T1 (pl) |
WO (1) | WO2017069628A2 (pl) |
ZA (1) | ZA201802758B (pl) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3110846B1 (en) | 2014-02-28 | 2020-08-19 | Merus N.V. | Antibodies that bind egfr and erbb3 |
CN106536556B (zh) * | 2014-04-04 | 2020-02-07 | 生态学有限公司 | 结合lgr5的人源化抗体 |
CA3002957A1 (en) | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
JP2019509322A (ja) | 2016-03-22 | 2019-04-04 | バイオノミクス リミテッド | 抗lgr5モノクローナル抗体の投与 |
JP7617603B2 (ja) | 2017-01-11 | 2025-01-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | R-スポンジン(rspo)サロゲート分子 |
AU2018211985A1 (en) * | 2017-01-26 | 2019-07-18 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
CA3063849A1 (en) | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
AU2018297061B2 (en) * | 2017-07-06 | 2021-05-06 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
EP3649155A1 (en) * | 2017-07-06 | 2020-05-13 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
CN111936514A (zh) * | 2018-03-30 | 2020-11-13 | 美勒斯公司 | 多价抗体 |
CA3104868A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
AU2019416324A1 (en) * | 2018-12-27 | 2021-07-22 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Bispecific antibody for membrane clearance of target receptors |
CN114249818A (zh) | 2018-12-31 | 2022-03-29 | 美勒斯公司 | 截短的多价多元体 |
JP7443376B2 (ja) * | 2018-12-31 | 2024-03-05 | メルス ナムローゼ フェンノートシャップ | 混合結合ドメイン |
CN114426578A (zh) * | 2019-02-14 | 2022-05-03 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
BR112021016094A2 (pt) * | 2019-02-14 | 2021-10-26 | Merus N.V. | Combinações de porções de ligação que se ligam ao egfr, her2 e her3 |
EP3931224A4 (en) | 2019-02-26 | 2023-03-01 | Janssen Biotech, Inc. | COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES |
AU2020251578A1 (en) * | 2019-04-04 | 2021-10-28 | Ono Pharmaceutical Co., Ltd. | Bispecific antibody |
JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
CA3151641A1 (en) | 2019-08-19 | 2021-02-25 | Merus N.V. | Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor |
CA3159745A1 (en) * | 2019-11-01 | 2021-05-06 | The Regents Of The University Of California | Degradation of surface proteins using bispecific binding agent |
WO2021176034A1 (en) * | 2020-03-05 | 2021-09-10 | Umc Utrecht Holding B.V. | Membrane ubiquitin ligases to target protein degradation |
BR112022021345A2 (pt) | 2020-04-24 | 2022-12-27 | Merus Nv | Tratamento de cânceres com um anticorpo que se liga a lgr5 e egfr |
EP4168442A1 (en) * | 2020-06-18 | 2023-04-26 | UMC Utrecht Holding B.V. | Screening method for effective target - e3 ligase combinations |
CN113862326B (zh) * | 2020-09-08 | 2024-07-05 | 复旦大学 | KREMEN1和/或ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用 |
KR20230120125A (ko) | 2020-12-15 | 2023-08-16 | 메뤼스 엔.페. | Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료 |
EP4262867A1 (en) | 2020-12-18 | 2023-10-25 | Merus N.V. | Antibody composition |
CN114853889B (zh) * | 2021-02-03 | 2024-03-01 | 中国科学院动物研究所 | 针对人gpr48的单克隆抗体及其应用 |
CN113307882B (zh) * | 2021-05-12 | 2022-12-20 | 东北大学 | 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物 |
EP4413037A1 (en) | 2021-10-06 | 2024-08-14 | Merus N.V. | Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr |
WO2024136658A1 (en) | 2022-12-23 | 2024-06-27 | Merus N.V. | Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor |
TW202432606A (zh) | 2022-12-28 | 2024-08-16 | 荷蘭商美勒斯公司 | 使用結合egfr的抗體及細胞毒性藥物的組合之癌症治療 |
CN116082510B (zh) * | 2023-03-07 | 2023-12-05 | 四川尚锐生物医药有限公司 | 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
CA2111858A1 (en) | 1991-07-15 | 1993-02-04 | James S. Crowe | Production of antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE29706518U1 (de) | 1997-04-11 | 1997-05-22 | E. Missel GmbH & Co., 70374 Stuttgart | Trägersystem für Bade-, Dusch- oder Whirlwannen |
ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
ES2378272T3 (es) | 1999-04-15 | 2012-04-10 | Crucell Holland B.V. | Producción de proteína recombinante en una célula humana |
DE29915950U1 (de) | 1999-09-10 | 1999-12-30 | CMW Automation GmbH, 65594 Runkel | Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators |
US20070111201A1 (en) | 2001-04-30 | 2007-05-17 | Benjamin Doranz | Reverse transfection of cell arrays for structural and functional analyses of proteins |
CA2450020C (en) | 2001-07-04 | 2013-08-13 | Chromagenics B.V. | Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using dna sequences |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20050130224A1 (en) | 2002-05-31 | 2005-06-16 | Celestar Lexico- Sciences, Inc. | Interaction predicting device |
AU2003250074B2 (en) | 2002-07-18 | 2010-09-09 | Merus N.V. | Recombinant production of mixtures of antibodies |
CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
WO2005000894A2 (en) | 2003-06-25 | 2005-01-06 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
AU2005250499B2 (en) | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008531557A (ja) | 2005-02-23 | 2008-08-14 | メリマック ファーマシューティカルズ インコーポレーティッド | 生物活性を調節するための二重特異性結合剤 |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
US8580263B2 (en) | 2006-11-21 | 2013-11-12 | The Regents Of The University Of California | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
US7846440B2 (en) | 2007-02-16 | 2010-12-07 | Merrimack Pharmaceuticals, Inc. | Antibodies against ErbB3 and uses thereof |
ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
US7705103B2 (en) | 2007-06-22 | 2010-04-27 | 3M Innovative Properties Company | Polydiorganosiloxane polyoxamide copolymers |
ES2553169T5 (es) | 2007-07-02 | 2023-11-30 | Oncomed Pharm Inc | Composiciones y métodos para el tratamiento y el diagnóstico del cáncer |
EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
MX350962B (es) | 2008-01-07 | 2017-09-27 | Amgen Inc | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. |
AU2009211148B2 (en) | 2008-02-05 | 2014-08-28 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
SI2147594T1 (sl) | 2008-06-27 | 2014-02-28 | Merus B.V. | Protitelo proizvajajoči ne-humani sesalci |
JP5719298B2 (ja) | 2008-08-29 | 2015-05-13 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組換え抗上皮増殖因子受容体抗体組成物 |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
CN102460152B (zh) | 2009-01-15 | 2014-11-26 | 美国控股实验室公司 | 通过测量Her-3确定患者反应的方法 |
EP2389392A1 (en) | 2009-01-26 | 2011-11-30 | Genmab A/S | Methods for producing mixtures of antibodies |
EP2408817B1 (en) | 2009-03-20 | 2016-03-16 | F.Hoffmann-La Roche Ag | Bispecific anti-her antibodies |
US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
SG178509A1 (en) | 2009-08-21 | 2012-04-27 | Merrimack Pharmaceuticals Inc | Antibodies against the ectodomain of erbb3 and uses thereof |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2496598B1 (en) | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
SI2505654T2 (sl) | 2010-02-08 | 2020-08-31 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
JP2014511383A (ja) | 2011-02-24 | 2014-05-15 | メリマック ファーマシューティカルズ インコーポレーティッド | 抗ErbB3剤を含む併用療法 |
AU2012229062A1 (en) | 2011-03-15 | 2013-04-11 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to ErbB pathway inhibitors |
JP2014511836A (ja) | 2011-03-25 | 2014-05-19 | グレンマーク ファーマシューティカルズ, エセ.アー. | ヘテロ二量体免疫グロブリン |
GB201106395D0 (en) * | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
WO2012156309A1 (en) | 2011-05-13 | 2012-11-22 | Millegen | Antibodies against her3 |
CA2840461A1 (en) | 2011-06-20 | 2012-12-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbb3 antibody |
BR112014000765A2 (pt) * | 2011-07-15 | 2017-06-13 | Oncomed Pharm Inc | agentes de ligação a rspo e seus usos |
US9567827B2 (en) | 2013-07-15 | 2017-02-14 | Downhole Technology, Llc | Downhole tool and method of use |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
KR20140069331A (ko) | 2011-09-30 | 2014-06-09 | 리제너론 파아마슈티컬스, 인크. | 항-ErbB3 항체 및 이의 용도 |
BR112014012539B1 (pt) | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
BR112014013495A8 (pt) | 2011-12-05 | 2017-06-13 | Novartis Ag | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 |
EA202092280A3 (ru) | 2011-12-05 | 2021-09-30 | Новартис Аг | Антитела к рецептору эпидермального фактора роста 3 (her3) |
CN102448183A (zh) | 2012-01-18 | 2012-05-09 | 大唐移动通信设备有限公司 | 一种Uu接口重配置方法及设备 |
US9702824B2 (en) | 2012-03-09 | 2017-07-11 | Promega Corporation | pH sensors |
KR20140148388A (ko) | 2012-03-27 | 2014-12-31 | 제넨테크, 인크. | Her3 억제제와 관련된 진단 및 치료 |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
CN114163530A (zh) | 2012-04-20 | 2022-03-11 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗-egfr抗體及其用途 |
AU2013324527B9 (en) | 2012-09-27 | 2018-07-26 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
EP2906591A1 (en) | 2012-10-15 | 2015-08-19 | Universität Zürich | Bispecific her2 ligands for cancer therapy |
PL2922872T3 (pl) | 2012-11-21 | 2019-03-29 | Janssen Biotech, Inc. | Bispecyficzne przeciwciała przeciwko egfr/c-met |
WO2014121196A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US20160319034A1 (en) * | 2013-03-14 | 2016-11-03 | Oncomed Pharmaceuticals, Inc. | Met-binding agents and uses thereof |
US20160041171A1 (en) | 2013-04-05 | 2016-02-11 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
JP2016520586A (ja) | 2013-05-08 | 2016-07-14 | ザイムワークス,インコーポレイテッド | 二重特異性her2およびher3抗原結合性構築物 |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
US9551208B2 (en) | 2013-08-26 | 2017-01-24 | Halliburton Energy Services, Inc. | Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation |
US10519247B2 (en) | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
EP3110846B1 (en) | 2014-02-28 | 2020-08-19 | Merus N.V. | Antibodies that bind egfr and erbb3 |
ES2826774T3 (es) | 2014-02-28 | 2021-05-19 | Merus Nv | Anticuerpo que se une a ERBB-2 y ERBB-3 |
LT3126388T (lt) * | 2014-03-11 | 2019-08-26 | Regeneron Pharmaceuticals, Inc. | Antikūnai prieš egfrviii ir jų panaudojimo būdai |
CN106536556B (zh) | 2014-04-04 | 2020-02-07 | 生态学有限公司 | 结合lgr5的人源化抗体 |
MA41123A (fr) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
US10383945B2 (en) * | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
LT3115376T (lt) | 2015-07-10 | 2018-11-12 | Merus N.V. | Antikūnai, kurie jungiasi su žmogaus cd3 |
CA3002957A1 (en) | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
JP6946304B2 (ja) * | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法 |
EP3600411A1 (en) | 2017-03-31 | 2020-02-05 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
CA3063849A1 (en) | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
SG11202106764YA (en) * | 2018-12-27 | 2021-07-29 | Gigagen Inc | Anti-ctla-4 binding proteins and methods of use thereof |
-
2016
- 2016-10-21 CA CA3002957A patent/CA3002957A1/en active Pending
- 2016-10-21 MA MA45517A patent/MA45517B1/fr unknown
- 2016-10-21 MD MDE20180831T patent/MD3365373T2/ro unknown
- 2016-10-21 CN CN202211112405.5A patent/CN115925944A/zh active Pending
- 2016-10-21 PL PL16794080T patent/PL3365373T3/pl unknown
- 2016-10-21 ES ES16794080T patent/ES2865482T3/es active Active
- 2016-10-21 KR KR1020187014570A patent/KR20180100305A/ko not_active Application Discontinuation
- 2016-10-21 MX MX2018004988A patent/MX2018004988A/es unknown
- 2016-10-21 SM SM20210230T patent/SMT202100230T1/it unknown
- 2016-10-21 EP EP21161572.9A patent/EP3912998A3/en active Pending
- 2016-10-21 MA MA054760A patent/MA54760A/fr unknown
- 2016-10-21 CN CN201680065283.5A patent/CN108602888B/zh active Active
- 2016-10-21 EA EA201890866A patent/EA201890866A1/ru unknown
- 2016-10-21 NZ NZ74229016A patent/NZ742290A/en unknown
- 2016-10-21 WO PCT/NL2016/050726 patent/WO2017069628A2/en active Application Filing
- 2016-10-21 SG SG11201803359VA patent/SG11201803359VA/en unknown
- 2016-10-21 EP EP16794080.8A patent/EP3365373B1/en active Active
- 2016-10-21 HU HUE16794080A patent/HUE055222T2/hu unknown
- 2016-10-21 DK DK16794080.8T patent/DK3365373T3/da active
- 2016-10-21 SI SI201631138T patent/SI3365373T1/sl unknown
- 2016-10-21 LT LTEP16794080.8T patent/LT3365373T/lt unknown
- 2016-10-21 RS RS20210479A patent/RS61800B1/sr unknown
- 2016-10-21 BR BR112018008068A patent/BR112018008068A2/pt active Search and Examination
- 2016-10-21 AU AU2016340764A patent/AU2016340764B2/en active Active
- 2016-10-21 JP JP2018540363A patent/JP7296728B2/ja active Active
- 2016-10-21 US US15/770,317 patent/US11939394B2/en active Active
-
2018
- 2018-04-23 MX MX2022000302A patent/MX2022000302A/es unknown
- 2018-04-25 ZA ZA2018/02758A patent/ZA201802758B/en unknown
- 2018-10-12 HK HK18113062.6A patent/HK1253914A1/zh unknown
-
2021
- 2021-03-24 HR HRP20210483TT patent/HRP20210483T1/hr unknown
- 2021-04-19 CY CY20211100338T patent/CY1124108T1/el unknown
- 2021-11-05 JP JP2021181173A patent/JP2023008754A/ja active Pending
-
2023
- 2023-08-31 AU AU2023222928A patent/AU2023222928A1/en active Pending
- 2023-11-29 JP JP2023201785A patent/JP2024023445A/ja active Pending
-
2024
- 2024-02-02 US US18/431,642 patent/US20240343824A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1253914A1 (zh) | 抑制癌症生長的結合分子 | |
HK1251407A1 (zh) | 治療癌症的方法 | |
HK1252791A1 (zh) | 具有經修飾的j鏈的結合分子 | |
IL277261A (en) | Low molecular weight compounds for cancer treatment | |
PL3377516T3 (pl) | Kompozycja do leczenia nowotworu | |
GB201612520D0 (en) | Binding molecules | |
SG11201705583XA (en) | Cxcr4 binding molecules | |
HK1250944A1 (zh) | 用於治療癌症的方法 | |
GB201702091D0 (en) | Specific binding molecules | |
DK3292140T3 (en) | Immunterapeutikum mod cancer | |
HK1245120A1 (zh) | 用於癌症的新治療 | |
HK1250942A1 (zh) | 用於治療癌症的方法 | |
HK1250943A1 (zh) | 用於治療癌症的方法 | |
ZA201707024B (en) | Cancer treatment composition | |
GB2546773B (en) | Cancer | |
GB201522433D0 (en) | Cancer treatment | |
GB201508480D0 (en) | Cancer | |
IL258866A (en) | Binding molecules that inhibit cancer growth | |
PT3365373T (pt) | Moléculas de ligação que inibem o crescimento do cancro | |
GB201508729D0 (en) | Binding molecules | |
GB201503668D0 (en) | Liver cancer |